Sanofi scraps $11.6B Bioverativ drug trial after CIDP treatment failure
Sanofi scraps $11.6B Bioverativ drug trial after CIDP treatment failure
Sanofi scraps $11.6B Bioverativ drug trial after CIDP treatment failure
Sanofi has halted a major clinical trial for riliprubart, marking a significant setback for its rare disease portfolio. The decision follows an interim analysis showing the drug failed to treat CIDP effectively. The move raises questions about the broader success of Sanofi’s $11.6bn Bioverativ acquisition. Sanofi acquired Bioverativ in 2018 for $11.6bn, aiming to strengthen its rare disease pipeline. The company recently abandoned the Phase 3 MOBILIZE study of riliprubart, a C1s inhibitor designed to block the classical pathway of the human complement system. The trial involved 140 refractory CIDP patients across 134 global sites.
The drug’s failure has prompted Sanofi to review other ongoing studies of riliprubart. However, not all Bioverativ assets have underperformed. Altuviiio, approved in 2023 for haemophilia A, has shown strong commercial success, achieving Q1 2026 sales of around €325 million. Another C1s inhibitor from the same acquisition, Enjaymo, gained approval in 2022 before being sold to Recordati for $825 million. The abandonment of riliprubart puts pressure on the remaining Bioverativ pipeline to justify the acquisition’s cost. Altuviiio’s strong sales offer some validation, but doubts persist about the long-term value of the $11.6bn deal. Sanofi continues to assess the future of its other riliprubart studies.
How honey heals wounds, fights infections and even targets cancer cells
Forget sugar—honey is a medical marvel. Studies show it beats antibiotics, soothes psoriasis, and may even slow tumors. Here's why doctors are taking note.
Forgotten soldier's face reconstructed decades after his death in 1945 battle
A young soldier's features emerge from history after decades of silence. Now, his family may finally find closure—if DNA can bridge the past.
Sanofi scraps $11.6B Bioverativ drug trial after CIDP treatment failure
A major setback for Sanofi's rare disease ambitions. After a failed Phase 3 study, the future of its $11.6B Bioverativ deal hangs in the balance.
How Private Data Is Solving Global Health and Social Challenges
Your data could save lives—companies are turning user information into breakthroughs in medicine, public safety, and poverty relief. But will regulation slow progress?